Abstract
AbstractGrowing number of deaths due to decreased effects of antibiotics has increased the need for new antimicrobial drugs. Studies on the pharmacological effect and toxicity of favipiravir, a new antiviral drug that was informally recommended by World Health Organization (WHO) for the treatment of Coronavirus Disease 2019 (COVID‐19) for a while, are limited and still ongoing. We first aimed to evaluate the antibacterial efficacy of favipiravir in silico. A second aim of the manuscript is to examine its antibacterial, antifungal, cytotoxic, antiviral and larvicidal effects in vitro. In this study, it was determined that favipiravir was effective in terms of in silico antibacterial, in vitro antibacterial, antifungal, cytotoxicity, antiviral and larvicidal activities. As a result, potential areas of use can be found in terms of activities under investigation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
